- Home
- EHC vs LEGN Comparison
EHC vs LEGN Comparison
Compare EHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHC
- LEGN
- Stock Information
- Founded
- EHC 1983
- LEGN 2014
- Country
- EHC United States
- LEGN United States
- Employees
- EHC N/A
- LEGN N/A
- Industry
- EHC Hospital/Nursing Management
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EHC Health Care
- LEGN Health Care
- Exchange
- EHC Nasdaq
- LEGN Nasdaq
- Market Cap
- EHC 12.3B
- LEGN 6.7B
- IPO Year
- EHC 1986
- LEGN 2020
- Fundamental
- Price
- EHC $124.04
- LEGN $34.41
- Analyst Decision
- EHC Strong Buy
- LEGN Strong Buy
- Analyst Count
- EHC 7
- LEGN 12
- Target Price
- EHC $136.71
- LEGN $73.36
- AVG Volume (30 Days)
- EHC 661.5K
- LEGN 1.1M
- Earning Date
- EHC 10-27-2025
- LEGN 11-11-2025
- Dividend Yield
- EHC 0.61%
- LEGN N/A
- EPS Growth
- EHC 30.39
- LEGN N/A
- EPS
- EHC 5.11
- LEGN N/A
- Revenue
- EHC $5,669,100,000.00
- LEGN $796,838,000.00
- Revenue This Year
- EHC $11.57
- LEGN $70.75
- Revenue Next Year
- EHC $8.79
- LEGN $52.47
- P/E Ratio
- EHC $24.43
- LEGN N/A
- Revenue Growth
- EHC 11.80
- LEGN 74.75
- 52 Week Low
- EHC $87.85
- LEGN $27.34
- 52 Week High
- EHC $127.15
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- EHC 52.09
- LEGN 44.28
- Support Level
- EHC N/A
- LEGN $32.70
- Resistance Level
- EHC $127.15
- LEGN $34.71
- Average True Range (ATR)
- EHC 1.84
- LEGN 1.20
- MACD
- EHC -4.83
- LEGN 0.01
- Stochastic Oscillator
- EHC 97.44
- LEGN 44.25
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.